cyrilzakka/clinical-trials huggingface dataset:
Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy

The aim of this study was to evaluate the effects of dexmedetomidine on renal function, hormonal and hemodynamic parameters in contrast media induced diabetic patients.

Contrast nephropathy may occur after using intravenous contrast media and may result in acute renal failure. Contrast nephropathy usually reversible but in some cases it can be permanent. This situation increase the time of hospitalization and mortality of the patients. Although the only proved prevention from contrast nephropathy method is hydration, infusion of dexmedetomidine may keep the renal functions.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled for percutaneous coronary angiography
* \> 18 yo
* Diabetic patients
* Creatinin value \< 3 mg/dl

Exclusion Criteria:

* Contrast agent hypersensitivity
* Pregnant patients
* Creatinin value ≥3mg/dl
* patients have acute renal failure
The Parkinson's Genetic Research Study

The Parkinson's Genetic Research Study (PaGeR), headed by Dr. Cyrus Zabetian, is searching for genes that increase the risk of developing Parkinson's disease (PD) and related disorders. The study is a joint effort by neurologists and researchers across the United States and is sponsored by the National Institutes of Health. The coordinating center for PaGeR is located at the University of Washington and the VA Puget Sound Health Care System in Seattle.

PaGeR is focusing on families in which two or more people have been diagnosed with PD. Past research suggests that such "multiplex" families might hold the key to the discovery of new PD genes.

To take part in PaGeR, participants will be asked to complete a questionnaire and to undergo an interview, a neurological exam, a short memory test, and a blood draw. Enrollment in the study usually takes between one and two hours. There is no cost to participate, and all study information is kept strictly confidential.

There are a number of designated sites across the country where families can enroll. However, for family members who are unable to travel to one of these sites, other arrangements can be made.

Eligibility Criteria:
Inclusion Criteria:

* Over 18 years of age
* Member of a family in which there are two or more living individuals who have been diagnosed with Parkinson's disease

Exclusion Criteria:

* Under 18 years of age
Acupoint Thermal Radiation Characteristics in Adolescents with MDD

Modern studies have confirmed that skin temperature changes at acupoints when the body is under pathological conditions. This suggests that changes in the thermal radiation characteristics of acupoints can objectively respond to the symptoms of a disease. In this study, the investigators first evaluated reproducibility of acupoint temperature measurement by IRT. Secondly, the investigators explored the thermal radiation characteristics of MDD-related acupoints, built the diagnostic model for adolescent depression severity and the diagnostic model for MDD in adolescents based on acupoint temperature. Our research findings will provide new ideas, methods and visualisations for early screening, auxiliary diagnosis and condition assessment of MDD in adolescents.

A total of 100 subjects were included, 60 adolescent with MDD (MDD group) and 40 healthy controls (HC group). All subjects accepted IRT detection.The random selection of 30 adolescent with MDD allowed the collection of the bilateral same name acupoint temperatures. Intra- and inter-observer reproducibility for the patients were examined in some randomly selected patients by 2 investigators and 2 investigators both made 2 independent measurements in a week. 30 MDD subjects were detected the bilateral same name acupoint temperatures.

Eligibility Criteria:
Inclusion Criteria:

Inclusion criteria for the healthy control participants:

* 12years≤ age\<18 years;
* SDS score \<53;
* Adolescents with normal cognitive function can cooperate with the study;
* Adolescents and guardians agree to the study plan and sign the informed consent form.

Inclusion criteria for the major depression disorder participants:

* 12years≤ age\<18 years;
* Self-rating Depression Scale (SDS) score ≥ 53;
* Language, cognition and communication ability are normal;
* Patients and guardians agree to the study plan and sign the informed consent form.

Exclusion Criteria:

Exclusion criteria both for the healthy control participants and major depression disorder participants:

* Severe anxiety, schizophrenia, or other serious mental illnesses;
* There are pigmentation, redness, infection or scarring on the skin at the site of detection;
* Patients with severe systemic diseases and their complications, serious infections, and major diseases of viscera, tissues, and systems;
* Female patients who were pregnant or lactating;
* Female patients who were during, or in proximity (±2 days) to their menstruation or ovulation;
* Patients with a body temperature ≥37.3°C;
* Inability to cooperate during the examination;
* Participating in any other clinical trials.
Effects of Abdominal Nerve Block on Postoperative Recovery in Patients Undergoing Gastrointestinal Surgery

To explore the effect of general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) on the recovery of patients with gastrointestinal tumor after surgical treatment.


Eligibility Criteria:
Inclusion Criteria:

1. Aged 18 to 80 years.
2. ASA 1-3.
3. Clinical diagnosis of gastric carcinoma and colorectal cancer without metastasis.
4. Surgery for gastrointestinal surgery.

Exclusion Criteria:

1. Patients and their family members refuse to accept the clinical trial;
2. Complicated with acute cholangitis, gastrointestinal bleeding or ascites, etc.;
3. Hepatic encephalopathy, psychosis or neuropathy;
4. Body weight for acid-base and electrolyte imbalances, endotoxemia, and cachexia decreased by more than 2% or 5% in the past 2 months or 6 months.
5. Uncontrolled hypertentsion, coronary heart disease, diabetes.
Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair

The primary objective of this study is to determine the efficacy of administering a course of postoperative oral steroids in pediatric patients undergoing proximal hypospadias repair as prevention against complications. Specifically, the study aims to assess if the steroids i) decrease the incidence of wound breakdown, fistula formation, stenosis or stricture formation, and the need for subsequent redo-hypospadias surgeries and/or fistula repairs and ii) improve the quality of wound healing including the overall cosmetic appearance of the phallus (i.e. location of the urethral meatus).

Hypospadias repair is a surgery that is, unfortunately, fraught with a high complication rate with problems that include urethrocutaneous fistula formation, complete wound breakdown, glans dehiscence, urethral diverticulum formation, retraction of the urethral meatus, urethral stricture, and meatal stenosis . Failure of a proximal hypospadias repair (i.e. the development of a post-operative complication) is unpredictable, and few modifiable risk factors having been identified. Complications necessitate subsequent surgical intervention for pediatric patients, which must be carried out under general anesthesia. Evidence regarding the harms of multiple general anesthetics for children is increasing. Additionally, with each surgical revision comes the morbidity associated with another post-surgical convalescence. Thus, any measure that can be gained as a way to increase the rate of success of proximal hypospadias repair would be of help to all pediatric urologists and patients with hypospadias. The proposed intervention of administering a 5 day course of placebo versus oral steroids at a dose equivalent to what is given for outpatient treatment of asthma exacerbations, is expected to have very low risk. This would be the only variation from the current practice and one that has never been studied in the past. Thus, it would be worthwhile to perform use scientific methods to determine if the administration of a short course of oral steroids is of benefit to healing and minimization of post-operative complications for hypospadias patients.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing proximal hypospadias repair

Exclusion Criteria:

* All patients currently taking steroids at the time of surgery or during the six-week recovery period as well as patients with betamethasone hypersensitivity will be excluded from the study. Selection will be based on parent willingness to allow the child to participate in the study.
Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment

While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel supplying blood to the brain is obstructed), bleeding or thromboembolism (a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel), limited data are available on the number of NVAF patients and the reasons why NVAF patients in Italy stop or change their treatment with blood thinners to prevent stroke or thromboembolism.

By following the NVAF patients in routine clinical practice in Italy who are treated with rivaroxaban to prevent stroke or systemic embolism researchers want to find out how many NVAF patients and for what reasons NVAF patients stopped or changed rivaroxaban treatment. Study data will be collected through patients' routine visits at their treating doctor over a period of 24 months for each patient.


Eligibility Criteria:
Inclusion Criteria:

* Age \>= 18
* Patient with a diagnosis of NVAF
* New user to rivaroxaban, naïve or non naïve to treatment with oral anticoagulant
* Patient for whom the decision to initiate treatment with rivaroxaban was made as per physician's routine treatment practice for prevention of stroke and non-central nervous system (CNS) systemic embolism
* Signed an informed consent

Exclusion Criteria:

* Patient with heart valve replacement
* Patient is participating in an investigational program with interventions outside of routine clinical practice
A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2

An Investigator-initiated, Randomized, Single-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of SARS-Cov-2 Post Exposure Prophylaxis and Safety of HH-120 nasal spray


Eligibility Criteria:
Inclusion Criteria:

* Participants aged 18 to 65 years.
* Participants who have close contact with a SARS-CoV-2 infected individual (index case) are required to be randomized within 72 hours upon close contact.
* Willing and able to provide written informed consent, or with a legal representative who can provide informed consent.

Exclusion Criteria:

* Have a history of severe allergy or hyper-sensitivity to inhaled allergen.
* Pregnant or breastfeeding women.
* Have participated, within the last 180 days prior to the screening, in a clinical study involving an investigational intervention of SARS-CoV-2 neutralizing antibody.
* Have other conditions not suitable for the study per investigator's discretion.
Citrate Anticoagulation for Postdilution Hemofiltration

This study evaluates a protocol for regional citrate anticoagulation in critically ill patients with acute kidney injury who are treated with continuous veno-venous haemofiltration in postdilution mode.

Acute kidney injury (AKI) requiring continuous renal replacement therapy (CCRT occurs in approx. 15 % of all intensive care patients. A sustained and prolonged filter running time is required to deliver an effective dialysis dose. This requires effective anticoagulation. Today, regional citrate anticoagulation (RCA) is preferred over systemic anticoagulation because of prolonged filter lifetimes and less adverse effects.

We here study prospectively patients with AKI who are treated with continuous veno-venous haemofiltration using an RCA protocol.

We will evaluate all parameters of CRRT including filter running times, delivered dialysis dose, causes for treatment interruption and control of pH and electrolytes.

Eligibility Criteria:
Inclusion Criteria:

* acute kidney injury
* critical illness and treatment at ICU

Exclusion Criteria:

* age \< 18 years
* pregnancy or breast feeding
* severe lactate acidosis ( \> 10 mmol/l) for longer than 6 hours and pH \< 7.2
Local Control After Robot-assisted Supraglottic Laryngectomy

Transoral robotic surgery is an option to treat supraglottic squamous cell carcinomas. Oncological outcomes 2 years after transoral robotic surgery for supraglottic laryngectomy were studied.


Eligibility Criteria:
Inclusion Criteria:

* Men or women over 18 years of age
* Patients with supra-glottic squamous cell carcinoma from T1 to T3, all stages N
* Patients with a robot assisted supra-glottic laryngectomy with at least 2 years follow-up

Exclusion Criteria:

* Patients for whom follow-up of at least 2 years has not been achieved;
* Major patients protected by the law (under guardianship or guardianship);
* Patients who expressed opposition to their participation in the study.
Effects of Sauna Bathing on Sleep, Mood and Stress

Sauna bathing is a popular, low-cost, and easily accessible type of whole-body thermotherapy that has been used for social, religious, health, and hygienic reasons for thousands of years. There is strong evidence to support the various physiological and psychological benefits of sauna bathing. The positive effects of regular sauna use have been explained by a number of mechanisms of action, including increased cardiac output, reduced peripheral vascular resistance and other physiological changes in cardiovascular parameters such as decreased systolic and/or diastolic blood pressure. Additionally, the psychological impact of sauna bathing may occur due to a combination of factors that include the release of endorphins, relaxation, placebo effects, and psychological and social interactions that likely occur around frequent sauna activity. Taken together, it is possible that acute and regular sauna bathing may impact sleep quality.


Eligibility Criteria:
Inclusion Criteria:

* good general health assessed by physician
* written consent to participate

Exclusion Criteria:

* medication or dietary supplements, which could potentially impact the study outcomes
* history of sleep or neurological disorders
* regular sauna use
* professional athlete
* shift worker
Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients.

This phase IV study aims to assess the safety and the efficacy in intra ocular pressure of Geltim LP® 1 mg/g (0.1% unpreserved timolol maleate gel) in glaucomatous patients initially treated and stabilised by monotherapy of Xalatan® with ocular objective signs of intolerance to prostaglandin eye drops.

The primary objectives are to compare the safety and the efficacy of Geltim LP® 1mg/g eye drops versus Xalatan® eye drops with respect to:

The assessment of the ocular tolerance:

* Ocular symptoms
* Objective ocular signs.

The maintain of the IOP efficient lowering effect. Comparison between the 2 study products of the mean basal IOP after a 12 weeks treatment period (84 days ±7).

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent.
* Association of the 4 following criteria:

  1. - Bilateral primary open angle glaucoma or bilateral ocular hypertension already treated and controlled by mono-therapy of Xalatan® (1drop per day),
  2. - With local intolerance signs.

Exclusion Criteria:

* Presence of severe objective ocular sign.
* Any ocular hypertension other than primary ocular hypertension or primary chronic open angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma).
* Absolute defect in the ten degrees central point of the visual field.
* Best far corrected visual acuity ≤ 1/10.
In-hospital Versus DAy Care Hysterectomy in Transgender Men

In this trial 2 groups of transmen who are getting a hysterectomy will be compared: inpatient vs outpatient.

In this trial transmen who consultate for a hysterectomy are randomised over 2 groups: inpatient vs outpatient.

In the inpatient group the participant stays 1 night in the hospital after the laparoscopic hysterectomy. The outpatient group can leave the hospital the day of the operation. Standard care after laparoscopic hysterectomy is 2 nights hospital stay.

Through this trial the investigators would like to answer following questions:

* Is hysterectomy in dayclinic as safe as a hysterectomy in an outpatient setting?
* Is there a higher complication/re-admission rate with hysterectomy in outpatient setting?
* Are patients as satisfied with the length of hospital stay in an inpatient hysterectomy?
* Is the need for pain medication higher in the inpatient group? Do this patients experience more postoperative pain?
* Is there a loss in 'quality of life' with hysterectomy in inpatient setting?
* Are patients who have the hysterectomy in dayclinic more anxious/worried?

The primary objective is the satisfaction of the patient with the length of hospital stay. The other indicators will be seen as secondary outcomes.

Eligibility Criteria:
Inclusion Criteria:

* transgender man
* 18y or older
* registers for a total hysterectomy at the genderclinic of UZ Gent.

Exclusion Criteria:

* simultaneous planned breast surgery/scar corrections
* ASA score 3-4
* persons with mental retardation or severe psychiatric disorder
* persons without an adult caretaker / partner present the first night after discharge from the hospital
upREACH Perinatal Home Visitation Program

The purpose of this study is to assess the effectiveness of a new brief home visitation program delivered by non-nurse home visitors to 1) improve connections to community resources based on reported and assessed needs, 2) increase health self-efficacy, and 3) reduce maternal stress compared to a control group that receives standard care from an obstetric clinic.

Secondary administrative data on infant birth outcomes, health care use during the first year of life (appointment adherence), and interaction with government services (such as public assistance or child welfare) will be compared between the groups.

For the intervention group, we will secondarily also assess home visit compliance and satisfaction with the intervention.

Participants will be asked to complete questionnaires that include questions about the participant, their pregnancy, their feelings, their family, and their use of social/community services. Half of the women in this study will be randomly offered free home visitation services and the other half of women in this study will receive standard services from the clinic. The intervention group will be offered at least two free home visits with a non-nurse home visitor. During these visits, the home visitor will provide them with resources and tools to help the participant prepare for their baby. All participants will complete a second round of electronic surveys at approximately 2 months postpartum.

Intervention participant outcomes will be compared to a control group that receive standard care from an obstetric clinic.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant or postpartum women within 3 weeks postpartum (at enrollment)
* Receiving prenatal or postpartum care from Harris Health Clinic obstetric clinics
* Speak and read English or Spanish language.

Exclusion Criteria:

* Unable to speak or read English or Spanish language
* Women that do not receive perinatal or postpartum care at Harris Health obstetric clinics
* Women that are not pregnant or greater than 4 weeks postpartum (at enrollment)
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.


Eligibility Criteria:
Inclusion Criteria:

* To be enrolled in this study, subjects must be currently enrolled in a prior Amgen-sponsored conatumumab or AMG 479 study and are eligible according to the parent study to receive their next dose of conatumumab (with or without co-therapy), or AMG 479 alone.

Subjects must have their eligibility assessed for this study and be enrolled within 30 days of their last treatment on the parent protocol

Exclusion Criteria:

* Discontinued from a conatumumab study due to an adverse event considered by the investigator to be related to conatumumab treatment, including intolerance to conatumumab
* Subjects determined to have disease progression during their participation in the parent Amgen study
* Woman or man with partner of childbearing potential not consenting to use adequate contraceptive precautions ie, double barrier contraceptive methods (eg, diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last dose of protocol-specified therapy administration
* Subject is pregnant or breast feeding, or planning to become pregnant within 6 months after the last dose of protocol-specified therapy administration
* Male subject with a pregnant partner who is not willing to use a condom during treatment and for an additional 6 months after the last dose of protocol-specified therapy administration
* Subject has previously entered this study
* Subject will not be available for protocol required study visits, to the best of the subject and investigator's knowledge
* Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures